Trials / Completed
CompletedNCT03147677
Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan
A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- The Third Xiangya Hospital of Central South University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, multi-center, randomized, open-label, parallel-arm controlled study, for which a total of 216 patients with type 2 diabetic nephropathy (Stage II-IV) will be enrolled. The subjects will be randomized to three groups in 1:1:1 ratio. One group receive Alfacalcidol 0.25ug/day and Irbesartan 150mg/day for 16 consecutive weeks. The second group receive Alfacalcidol 0.25ug/day alone for 16 consecutive weeks. The third group receive Irbesartan 150mg/day alone for 16 consecutive weeks. All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alfacalcidol | |
| DRUG | Irbesartan |
Timeline
- Start date
- 2016-07-28
- Primary completion
- 2018-07-30
- Completion
- 2018-12-30
- First posted
- 2017-05-10
- Last updated
- 2019-10-10
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03147677. Inclusion in this directory is not an endorsement.